Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12613000512729
Ethics application status
Approved
Date submitted
6/05/2013
Date registered
8/05/2013
Date last updated
8/05/2013
Type of registration
Retrospectively registered
Titles & IDs
Public title
A study to evaluate safety and feasibility of zoledronic acid to prevent joint complication (osteonecrosis) following chemotherapy for acute lymphoblastic leukemia or lymphoma in children and adolescents.
Query!
Scientific title
A pilot study to evaluate safety and feasibility of administrating prophylactic doses of zoledronic acid to prevent symptomatic osteonecrosis following chemotherapy for acute lymphoblastic leukemia and lymphoma in children and adolescents.
Query!
Secondary ID [1]
282442
0
Nil known
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ZOL ALL
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Acute lymphoblastic leukemia
289051
0
Query!
Lymphoblastic lymphoma
289052
0
Query!
Osteonecrosis
289053
0
Query!
Condition category
Condition code
Cancer
289391
289391
0
0
Query!
Leukaemia - Acute leukaemia
Query!
Cancer
289392
289392
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Query!
Musculoskeletal
289393
289393
0
0
Query!
Other muscular and skeletal disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Group 1 :2 doses of Zoledronic acid (0.025mg/kg/dose ,Intravenous infusion) will be administered to children more than 10 years of age at diagnosis of Acute lymphoblastic leukemia /lymphoblastic lymphoma. First dose will be administered on Day 8 of chemotherapy and second dose will be administered 6 weeks after that.Serial blood tests and radiological interventions will be carried out according to the protocol.
Group 2 : Includes children between 5-10 years of age.They do not get Zoledronic acid.Blood tests and radiological intervention will be carried out according to the prtocol.This is done to determine baseline incidence of osteonecrosis in this population.
Query!
Intervention code [1]
287086
0
Prevention
Query!
Comparator / control treatment
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
289501
0
To determine safety and feasibility of administering 2 doses of Intravenous Zoledronic acid to children, more than 10 years of age at diagnosis, with acute lymphoblastic leukemia and lymphoblastic lymphoma for prevention of symptomatic chemotherapy related osteonecrosis.
Blood tests and radiological investigations will be done at given time intervals.
Query!
Assessment method [1]
289501
0
Query!
Timepoint [1]
289501
0
Baseline
24 hours,48 hours,72hours after both interventions
At 4 months 1 year and 2 years after second dose of Zoledronic acid.
Query!
Secondary outcome [1]
302622
0
To determine effect of 2 doses of Zoledronic acid in children more than 10 years of age on development of symptomatic osteonecrosis.
MRI of hip and knee joints,X-rays of hips,knees and spine and pain scores(visual analogue scale) will be determined at set intervals.
Query!
Assessment method [1]
302622
0
Query!
Timepoint [1]
302622
0
At 4 months, 1 year and 2 year after intervention
Query!
Secondary outcome [2]
302623
0
To determine baseline incidence of symptomatic and asymptomatic osteonecrosis in children from 5 years-10 years of age.
MRI scans of hips and knee joints and X-rays of hips,knees and spine will be done at set interavals.
Query!
Assessment method [2]
302623
0
Query!
Timepoint [2]
302623
0
At 4 months, 1 year and 2 years from baseline
Query!
Secondary outcome [3]
302624
0
To determine effect of albumin and cholesterol level on development of osteonecrosis.
Albumin and cholesterol will be monitored at baseline.MRI scans and X rays of hips and knees will be doen to detect changes of osteonecrosis.
Query!
Assessment method [3]
302624
0
Query!
Timepoint [3]
302624
0
At 4 months, 1 year and 2 year after baseline.
Query!
Secondary outcome [4]
302625
0
To determine effect of 2 doses of zoledronic acid on bone mineral density.
DEXA scans will be done at set intervals.
Query!
Assessment method [4]
302625
0
Query!
Timepoint [4]
302625
0
baseline,1 year and 2 years
Query!
Secondary outcome [5]
302626
0
To collect samples and facilitate studies of genetic polymorphisms in the genes putatively related to development of osteonecrosis.
Blood sample will be collected at diagnosis.
Query!
Assessment method [5]
302626
0
Query!
Timepoint [5]
302626
0
2 years
Query!
Eligibility
Key inclusion criteria
1) Diagnosis of Acute lymphoblastic leukemia or lymphoblastic lymphoma
2) Age more than 10 years for Zoledronic acid intervention(group1)
3) Age between 5yr-10 yr and able to have MRI without general anaesthetic for investigations (group2)
Query!
Minimum age
5
Years
Query!
Query!
Maximum age
16
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1) 25 hydroxy vitamin D< 50 nmol/L
2) Hypocalcemia corrected for albumin
3) Prior bisphosphonate use
4) Estimated glomerular filtration rate (GFR) <35ml/min/1.73 m2 at screening based on Schwartz formula
5) Diagnosis of active uveitis
6) History of primary bone disease (osteogenesis imperfecta, idiopathic juvenile osteoporosis, rickets/osteomalacia)
7) Unable to have MRI without general anaesthesia
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
11/10/2012
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
10
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
961
0
The Children's Hospital at Westmead - Westmead
Query!
Recruitment postcode(s) [1]
6819
0
2145 - Westmead
Query!
Funding & Sponsors
Funding source category [1]
287221
0
Hospital
Query!
Name [1]
287221
0
Oncology Department
The Childrens Hospital at Westmead
Query!
Address [1]
287221
0
Cnr Hawkesbury road and Hainsworth street
Westmead,NSW 2145
Query!
Country [1]
287221
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
Sydney Children's Hospital Network
Query!
Address
Cnr Hawkesbury Road and hainsworth Street
Westmead NSW 2145
Query!
Country
Australia
Query!
Secondary sponsor category [1]
285988
0
None
Query!
Name [1]
285988
0
Query!
Address [1]
285988
0
Query!
Country [1]
285988
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Summary
Brief summary
The study is evaluating the safety and feasibility of zoledronic acid to prevent joint complication (osteonecrosis) following chemotherapy for acute lymphoblastic leukemia or lymphoma in children and adolescents.
Who is it for? You or your child may be eligible to join this study if you/they are aged between 5 and 16 years and have been diagnosed with acute lymphoblastic leukemia or lymphoblastic lymphoma.
Trial details: In participants more than 10 years of age the drug zoledronic acid will be intravenously infused (i.e. administered directly into the vein) on day 8 of chemotherapy and again 6 weeks later (Group 1). Children between 5-10 years of age will not receive zoledronic acid (Group 2). Both groups will be regularly monitored by blood tests and radiological interventions for up to 2 years post treatment in order to determine the feasibility and safety of zoledronic acid and the incidence of osteonecrosis (joint complication of cancer treatment).
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
39782
0
Dr Bhavna Padhye
Query!
Address
39782
0
Oncology Department
The Children's Hospital at Westmead
Cnr Hawkesbury road and hainsworth street
Westmead,NSW 2145
Query!
Country
39782
0
Australia
Query!
Phone
39782
0
+61298450000
Query!
Fax
39782
0
Query!
Email
39782
0
[email protected]
Query!
Contact person for public queries
Name
39783
0
Dr Bhavna Padhye
Query!
Address
39783
0
Oncology Department
The Children's Hospital at Westmead
Cnr Hawkesbury road and hainsworth street
Westmead,NSW 2145
Query!
Country
39783
0
Australia
Query!
Phone
39783
0
+61298450000
Query!
Fax
39783
0
Query!
Email
39783
0
[email protected]
Query!
Contact person for scientific queries
Name
39784
0
Dr Bhavna Padhye
Query!
Address
39784
0
Oncology Department
The Children's Hospital at Westmead
Cnr Hawkesbury road and hainsworth street
Westmead,NSW 2145
Query!
Country
39784
0
Australia
Query!
Phone
39784
0
+61298450000
Query!
Fax
39784
0
Query!
Email
39784
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF